China Closes Gap, but US Leads Biotech Innovation

China now conducts more clinical drug trials than the U.S., signaling its growing influence in global biotechnology. However, a recent survey of senior U.S. leaders in industry and academia shows that the U.S. still maintains a lead in several critical biotech innovation areas.

The poll, conducted by Cure Innovation Index, found that China leads in two of six major biotech sectors: clinical development and supply chain. These strengths highlight China’s growing ability to scale biotech operations rapidly.

Meanwhile, the U.S. continues to dominate in technology transfer, capital access, commercialization, and talent. Respondents viewed both countries as roughly equal in scientific discovery, showing how competitive the global biotech race has become.

Cure CEO Seema Kumar said the U.S. remains ahead, but confidence is weakening as China continues to gain momentum. Many respondents described China as a major long-term threat to American biotech leadership.

China Expands Its Presence in Global Biotechnology

The survey findings were presented in San Diego during the annual meeting of the Biotechnology Innovation Organization. Industry leaders highlighted China’s growing influence in drug development and manufacturing.

In recent years, multinational pharmaceutical companies have increasingly expanded their pipelines with drug candidates developed in China. Lower costs, streamlined regulations, and government-backed support have accelerated this shift.

According to research from Georgetown University, the U.S. share of early drug development programs dropped from 48% in 2015 to around 37% in 2024. During the same period, China’s global share surged from 8% to more than 32%.

Drugmakers are licensing molecules from China at a faster pace, often investing relatively small upfront payments with hopes of developing blockbuster treatments worth billions of dollars.

U.S. Retains Strength in Commercialization and Market Power

The rapid growth of China’s biotech sector has raised concerns in Washington. The National Security Commission on Emerging Biotechnology warned that China has built a vertically integrated biotech ecosystem capable of challenging U.S. leadership.

In response, the Biosecure Act was signed into law to restrict federal agencies from conducting business with certain non-U.S. biotech firms. This reflects growing national security concerns around biotechnology.

Despite China’s speed and scale, the U.S. continues to hold major advantages in scientific quality, talent, and access to the world’s most valuable healthcare market. These strengths remain key drivers of long-term biotech leadership.

Commercialization remains America’s biggest advantage. The U.S. accounted for 53% of the global pharmaceutical market in 2025, strengthening its position as the world’s leading market for biotech innovation and drug commercialization.

Read : Why LLM API Keys Must Be Treated as Tier-Zero Secrets

Research Funding Emerges as a Major U.S. Concern

Interestingly, survey respondents identified U.S. research funding cuts as a greater threat than direct competition from China. Many believe funding instability could weaken America’s long-term innovation capacity.

Seema Kumar noted that the U.S. already has the necessary ingredients to maintain leadership, including talent, infrastructure, and market access. However, funding models may need urgent modernization.

She emphasized the need to strengthen financing for institutions such as the National Institutes of Health and improve the nation’s clinical development infrastructure. These changes could help preserve America’s competitive edge.

As the biotech race intensifies, the future of innovation may depend not only on global competition but also on how effectively the U.S. invests in its own research ecosystem.